{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T07:47:13Z","timestamp":1775634433568,"version":"3.50.1"},"reference-count":33,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic neutrophilic leukemia (CNL) is a very rare myeloid neoplasm characterized by peripheral blood neutrophilia and a hypercellular marrow with increased granulopoiesis. An activating mutation in CSF3R is present in 80% to 90% of cases. CNL displays some biological overlap in terms of clinical presentation and behavior, as well as genetic profile, with several other myeloid neoplasms, particularly myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) and other MPN. Distinguishing these related entities can be challenging, requires close attention to peripheral blood and bone marrow morphology, and can be informed by the mutation pattern: CNL is strongly associated with CSF3R mutation, usually lacks JAK2, MPL, or CALR mutations, and, by definition, lacks BCR::ABL1 rearrangement. Pitfalls in diagnosis include subjectivity in assessing neutrophil dysplasia and distinguishing true neoplastic neutrophilia from reactive neutrophilias that may be superimposed upon or occur as a manifestation of the progression of other myeloid neoplasms. Accurate distinction between neutrophilic myeloid neoplasms is important, as it helps guide patient management and may disclose specific genetic lesions amenable to targeted therapy.<\/jats:p>","DOI":"10.1182\/hematology.2024000555","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:03:00Z","timestamp":1733497380000},"page":"270-278","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["The spectrum of Ph-negative disease: CNL and <i>CSF3R<\/i>-related disorders"],"prefix":"10.1182","volume":"2024","author":[{"given":"Robert P.","family":"Hasserjian","sequence":"first","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"7","key":"2024121115403388000_hem2024000555C1","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/ajh.27321","article-title":"Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management","volume":"99","author":"Szuber","year":"2024","journal-title":"Am J Hematol"},{"issue":"19","key":"2024121115403388000_hem2024000555C2","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"2024121115403388000_hem2024000555C3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ajh.26481","article-title":"Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management","volume":"97","author":"Szuber","year":"2022","journal-title":"Am J Hematol"},{"issue":"9","key":"2024121115403388000_hem2024000555C4","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2013.122","article-title":"CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"2024121115403388000_hem2024000555C5","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1038\/leu.2017.126","article-title":"Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations","volume":"31","author":"Zhang","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"2024121115403388000_hem2024000555C6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3390\/cancers16020313","article-title":"Myeloproliferative neoplasms: diseases mediated by chronic activation of signal transducer and activator of transcription (STAT) proteins","volume":"16","author":"Liongue","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2024121115403388000_hem2024000555C7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood-2016-10-695981","article-title":"Genomics of chronic neutrophilic leukemia","volume":"129","author":"Maxson","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2024121115403388000_hem2024000555C8","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1007\/s00277-023-05550-6","article-title":"Research progress of additional pathogenic mutations in chronic neutrophilic leukemia","volume":"103","author":"Gao","year":"2024","journal-title":"Ann Hematol"},{"issue":"9","key":"2024121115403388000_hem2024000555C9","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1182\/bloodadvances.2022008204","article-title":"CNL and aCML should be considered as a single entity based on molecular profiles and outcomes","volume":"7","author":"Carre\u00f1o-Tarragona","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2024121115403388000_hem2024000555C10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ajh.24031","article-title":"ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia","volume":"90","author":"Elliott","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"2024121115403388000_hem2024000555C11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-018-0058-7","article-title":"CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival","volume":"8","author":"Szuber","year":"2018","journal-title":"Blood Cancer J"},{"issue":"10","key":"2024121115403388000_hem2024000555C12","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO.19.00895","article-title":"Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia","volume":"38","author":"Dao","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024121115403388000_hem2024000555C13","doi-asserted-by":"crossref","first-page":"1014671","DOI":"10.3389\/fonc.2022.1014671","article-title":"Case report: chronic neutrophilic leukemia associated with monoclonal gammopathies. A case series and review of genetic characteristics and practical management","volume":"12","author":"Vermeersch","year":"2022","journal-title":"Front Oncol"},{"key":"2024121115403388000_hem2024000555C14","doi-asserted-by":"crossref","first-page":"100739","DOI":"10.1016\/j.blre.2020.100739","article-title":"CIN or not: an approach to the evaluation and management of chronic idiopathic neutrophilia","volume":"46","author":"Otieno","year":"2021","journal-title":"Blood Rev"},{"issue":"8","key":"2024121115403388000_hem2024000555C15","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20090693","article-title":"An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia","volume":"206","author":"Plo","year":"2009","journal-title":"J Exp Med"},{"issue":"1","key":"2024121115403388000_hem2024000555C16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MOH.0000000000000479","article-title":"Mechanisms of leukemic transformation in congenital neutropenia","volume":"26","author":"Link","year":"2019","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"2024121115403388000_hem2024000555C17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.hoc.2012.10.004","article-title":"ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiology","volume":"27","author":"Horwitz","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"2024121115403388000_hem2024000555C18","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood.V88.7.2410.bloodjournal8872410","article-title":"Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR\/ABL with C3\/A2 junction)","volume":"88","author":"Pane","year":"1996","journal-title":"Blood"},{"issue":"11","key":"2024121115403388000_hem2024000555C19","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.2019000611","article-title":"Genomic landscape of neutrophilic leukemias of ambiguous diagnosis","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2024121115403388000_hem2024000555C20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00428-022-03465-7","article-title":"Advances in myelodysplastic\/myeloproliferative neoplasms","volume":"482","author":"Prakash","year":"2023","journal-title":"Virchows Arch"},{"issue":"3","key":"2024121115403388000_hem2024000555C21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41408-021-00449-9","article-title":"CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes","volume":"11","author":"Bezerra","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"2024121115403388000_hem2024000555C22","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1080\/10428194.2023.2227750","article-title":"CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature","volume":"64","author":"Guastafierro","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2024121115403388000_hem2024000555C23","first-page":"100248","article-title":"Myelodysplastic syndrome transforming to atypical chronic myeloid leukemia shows changes in its mutation allele frequency and acquisition of new mutations","volume":"15","author":"Nm","year":"2021","journal-title":"Leuk Res Rep"},{"issue":"16","key":"2024121115403388000_hem2024000555C24","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","article-title":"Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1","volume":"5","author":"Obiorah","year":"2021","journal-title":"Blood Adv"},{"key":"2024121115403388000_hem2024000555C25","article-title":"VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic): clinical review in a rapidly emerging field [published online 21 May 2024]","author":"Phan","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2024121115403388000_hem2024000555C26","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s00277-018-3402-x","article-title":"The co-occurrence of driver mutations in chronic myeloproliferative neoplasms","volume":"97","author":"Boddu","year":"2018","journal-title":"Ann Hematol"},{"issue":"11","key":"2024121115403388000_hem2024000555C27","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1038\/s41379-022-01118-3","article-title":"Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations","volume":"35","author":"Tashakori","year":"2022","journal-title":"Mod Pathol"},{"issue":"26","key":"2024121115403388000_hem2024000555C28","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1182\/blood.2019001385","article-title":"JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"issue":"21","key":"2024121115403388000_hem2024000555C29","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2024121115403388000_hem2024000555C30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14737140.2023.2192930","article-title":"Pemigatinib for the treatment of myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"23","author":"Freyer","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"11","key":"2024121115403388000_hem2024000555C31","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.2019002302","article-title":"Illuminating neutrophilic myeloid neoplasms","volume":"134","author":"Hasserjian","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2024121115403388000_hem2024000555C32","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2024121115403388000_hem2024000555C33","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/270\/2346598\/270hasserjian.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/270\/2346598\/270hasserjian.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T20:07:23Z","timestamp":1733947643000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/270\/526156\/The-spectrum-of-Ph-negative-disease-CNL-and-CSF3R"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000555","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}